CYTK
Cytokinetics, Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +11.8% ·
share flow +3.0% ·
net new positions +5.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 11.48K | $711,878 | n/a | −1 |
| Q2 2026 | 126 | +7 | 95.69M | $8.15B | +10 | −4 |
| Q1 2026 | 123 | +1 | 87.96M | $5.79B | +8 | −8 |
| Q4 2025 | 121 | -1 | 92.45M | $5.87B | +2 | −2 |
| Q3 2025 | 19 | +2 | 69.14M | $3.80B | +2 | −1 |
| Q2 2025 | 15 | -2 | 62.06M | $2.05B | n/a | −2 |
| Q1 2025 | 14 | +1 | 26.36M | $1.06B | +1 | n/a |
| Q4 2024 | 13 | -1 | 25.19M | $1.18B | n/a | −1 |
| Q3 2024 | 13 | +2 | 19.21M | $1.01B | +2 | n/a |
| Q2 2024 | 11 | n/a | 17.42M | $943.61M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 15.53M | -1.0% | $853.30M | 0.0% | ▼ Trim | 2 | SEC ↗ ×17 |
| 2 | Fidelity (FMR) ✦ | 13.09M | +16.2% | $719.52M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | The Vanguard Group ✦ (passive) | 11.86M | -1.1% | $651.65M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 4 | Wellington Management ✦ | 7.41M | -5.3% | $407.17M | 0.1% | ▼ Trim | 6 | SEC ↗ ×8 |
| 5 | State Street Global Advisors ✦ (passive) | 5.62M | -11.8% | $308.73M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | JPMorgan Chase ✦ | 3.09M | n/a | $169.59M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 7 | Geode Capital Management ✦ (passive) | 3.04M | +1.5% | $167.11M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 2.37M | +26.8% | $130.08M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Goldman Sachs Group ✦ | 1.63M | n/a | $89.84M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 10 | Morgan Stanley ✦ | 1.52M | n/a | $83.60M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 11 | Citadel Advisors ✦ | 1.39M | +6.7% | $76.18M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 12 | Fisher Asset Management ✦ | 761.59K | +3.8% | $41.86M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 513.29K | +47.6% | $28.21M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 14 | Point72 Asset Management ✦ | 471.48K | New | $25.91M | 0.1% | New | 1 | SEC ↗ |
| 15 | Millennium Management ✦ | 342.53K | -25.3% | $18.83M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 289.97K | +2752.0% | $15.94M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | Marshall Wace ✦ | 178.98K | +743.2% | $9.84M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 18 | Adage Capital Partners ✦ | 38.00K | New | $2.09M | 0.0% | New | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 13.60K | -28.7% | $747,621 | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $25.91M | 0.1% |
| Adage Capital Partners | $2.09M | 0.0% |
Exited
| Norges Bank | $39.12M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 437 holders, 145.17M shares, $8.22B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.50K sh · $224,035
Officer, Director · 7.50K sh · $471,600
Officer · 3.50K sh · $214,830
Officer, Director · 7.50K sh · $490,950
Officer · 3.50K sh · $239,015
Officer, Director · 97.93K sh · $6.79M
Director · 1.00K sh · $72,130
Officer, Director · 7.50K sh · $550,800
Director · 1.00K sh · $74,660
Officer · 3.50K sh · $264,110
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology